Daniel Geffken

Daniel Geffken brings more than 30 years of experience in the life science industry to Vigeo Therapeutics. He is the founder and managing director of Danforth Advisors, a financial consulting firm for life science and healthcare companies that has assisted over 300 clients since its founding in 2011. He has served as CFO and strategic consultant to numerous companies, including Apellis Pharmaceuticals, Cidara Therapeutics, Cabaletta Bio, Inc., Homology Medicines, Stealth BioTherapeutics, and Transkaryotic Therapies. Since 2013, he has participated in seven initial public offerings. Over the course of his career, he has raised more than $1 billion in equity and debt securities for life science companies. Daniel holds a BS from The Wharton School, University of Pennsylvania, and an MBA from Harvard Business School.